Last week, we announced a significant milestone in the global mission of our company, one that will allow us to commercialize EYE-SYNC into the 27 countries that make up the European Union (EU).
Read articleThis month, we’ll be introducing our newest concussion product feature, the objective convergence measurement. This assessment paradigm features automated measures of both eyes as they follow a target as it moves from distance to the Near Point of Convergence and back to the start position.
Read articleMuch has been written and discussed about the impact that Digital Health is having on the evolution of clinical trials. While many agree that the COVID pandemic has greatly accelerated this process, others are split on the long-term impact Digital Health technologies project to ultimately have on patient outcomes.
Read articleWhile the pandemic is often credited with the accelerated adoption of digital health technologies among healthcare systems, particularly over the past two years, the competition among these organizations remains in its infancy.
Read articleDizziness related disorders are one of the most common forms of disability impacting quality of life today. Prevalent more among adults as they advance in age, dizziness has become one of the most commons type of chronic disabilities, affecting between 9-11% of the population.
Read articleThis month, we’ll be launching the newest integrated Virtual Reality (VR) headset from our partners at Pico Interactive, the Neo 3 Pro Eye.
Read articleAs technological innovation continues to outpace the evolution of healthcare practices, a fundamental shift is occurring. Patient centered care is no longer, having been replaced by consumer directed care. Consumers have shifted away from reactionary “sick” care options, opting to instead gravitate towards technology to monitor their own health and wellness.
Read articleFor many of us, 2021 can be summed up in just a few words.
Unpredictable. Scary. Chaotic. Promising. Hopeful.
Whatever your preference, it is likely we can agree that these uncertain times has forced all of us to think outside the box, to adapt to changing circumstances, and to learn new things and to do them in unique ways. We at SyncThink…
Read articleOur recent FDA clearance allowing EYE-SYNC as an aide to concussion diagnosis is a major milestone for diagnostic eye-tracking technology and its use in measuring prediction, a key brain function. SyncThink has spent decades studying this through rigorous clinical research, in order for patients and clinicians to benefit from the use of reliable, objective data to identify prediction related deficits, which are often discovered for the first time.
Read articleJune 3, 2021 In cased you missed it, check out our feature on us written by our partners at Tobii: https://blog.tobii.com/seeking-out-the-keys-to-scalability-to-democratize-brain-health-assessment By Maggie Ma For this innovation story, I sat with Scott Anderson, chief clinical officer at SyncThink — an expanding Palo-Alto tech company that has recently launched the third generation of its brain health […]
Read articleToday, SyncThink announced our newest partnership with Swedish technology firm and eye tracking provider Tobii, as well as Pico Interactive, a global leader in innovative Virtual Reality (VR) solutions, on our next generation EYE-SYNC product. In the coming weeks, we will begin shipping EYE-SYNC on Pico’s Neo 2 Eye, the first fully integrated VR headset […]
Read articleSyncThink is excited to announce the most significant software upgrade in the history of our EYE-SYNC platform.
Read articlePalo Alto, CA and Boston MA – August 10, 2022 – SyncThink, a next generation neurotechnology company, and makers of the award-winning EYE-SYNC technology, announces today that it has completed CE Mark certification, affirming conformity to European Medical Device Regulation (MDR), also known as ISO 13485. EYE-SYNC will be registered as a Class I medical device.
Read articlePalo Alto and Boston – March 29, 2022– SyncThink, a next gen neurotechnology company and developer of the award-winning EYE-SYNC technology, announces today the expansion of its clinical advisory board and the creation of a specific advisory panel of Physical Therapy providers, to assist the company with growing product demand and market opportunities.
Read articlePalo Alto and Boston–March 9, 2022– SyncThink, a next gen neurotechnology company and developer of the award-winning EYE-SYNC technology, announces today the expansion of its partnership with Pico Interactive, a global technology company that develops innovative VR and enterprise solutions, and the integration of its platform onto the Pico Neo 3 Pro Eye headset.
Read article